Nautilus Biotechnology to Announce First Quarter 2024 Financial Results on April 30, 2024

4/11/24 8:00:00 AM ET

Biotechnology: Laboratory Analytical Instruments

Industrials

Get the next $NAUT alert in real time by email

SEATTLE, April 11, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus"))), a company pioneering a single molecule protein analysis platform, today announced it will report financial results for the first quarter 2024 before market open on Tuesday, April 30, 2024.

The company's management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at: www.nautilus.bio.

About Nautilus Biotechnology, Inc.

With its corporate headquarters in Seattle, Washington and its research and development headquarters in San Carlos, California, Nautilus is a development stage life sciences company working to create a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus' mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit www.nautilus.bio.

Media Contact

[email protected]

Investor Contact

[email protected]

Get the next $NAUT alert in real time by email

Date	Price Target	Rating	Analyst
6/27/2024	$6.00	Buy	Guggenheim
6/3/2024	$3.00	Hold	Jefferies
1/6/2022	$8.00	Equal-Weight	Morgan Stanley
11/2/2021		Outperform	Cowen & Co.
8/4/2021	$10.00	Neutral	Goldman Sachs
7/13/2021	$13.00	Buy	Jefferies

Nautilus Biotechnology to Announce First Quarter 2024 Financial Results on April 30, 2024

Chat with this insight

Recent Analyst Ratings for $NAUT

$NAUT Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Senior VP, Operations Godwin Mary E. exercised 47,031 shares at a strike of $0.46 and sold $134,744 worth of shares (47,031 units at $2.87) (SEC Form 4)

Senior VP, Operations Godwin Mary E. exercised 35,000 shares at a strike of $0.46 and sold $99,869 worth of shares (35,000 units at $2.85) (SEC Form 4)

SEC Form 4 filed by Chief Marketing Officer Suzuki Kentaro

$NAUT Financials

Live finance-specific insights

Nautilus Biotechnology Reports Third Quarter 2024 Financial Results

Nautilus Biotechnology to Announce Third Quarter 2024 Financial Results on October 29, 2024

Nautilus Biotechnology Reports Second Quarter 2024 Financial Results

$NAUT SEC Filings

$NAUT Leadership Updates

Live Leadership Updates

$NAUT Market Insights

Live Market Insights

$NAUT Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 144 filed by Nautilus Biotechnolgy Inc.

SEC Form 144 filed by Nautilus Biotechnolgy Inc.

SEC Form 10-Q filed by Nautilus Biotechnolgy Inc.

Nautilus Biotechnology Appoints Mass Spectrometry Leader Ken Suzuki as Chief Marketing Officer

Nautilus Biotechnology Appoints Martin Huber, Ph.D., as Vice President of Biochemistry and Flow Cell Development

Nautilus Biotechnology Appoints Eric Spence as Vice President of Instrument Engineering and Ken Kuhn, Ph.D., as Vice President of Reagent and Platform Development

Nautilus Biotechnology shares are trading higher after Guggenheim initiated coverage on the stock with a Buy rating and a $6 price target.

Guggenheim Initiates Coverage On Nautilus Biotechnology with Buy Rating, Announces Price Target of $6

Jefferies Assumes Nautilus Biotechnology at Hold, Lowers Price Target of $3

Patel Sujal M bought $41,478 worth of shares (14,474 units at $2.87), increasing direct ownership by 0.14% to 10,064,488 units (SEC Form 4)

Patel Sujal M bought $99,054 worth of shares (35,526 units at $2.79), increasing direct ownership by 0.35% to 10,050,014 units (SEC Form 4)

$NAUT Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13D/A filed by Nautilus Biotechnolgy Inc. (Amendment)

SEC Form SC 13D/A filed by Nautilus Biotechnolgy Inc. (Amendment)

SEC Form SC 13G filed by Nautilus Biotechnolgy Inc.

$NAUT Press Releases

Fastest customizable press release news feed in the world

Nautilus Biotechnology Co-founder and Chief Scientist Parag Mallick, Ph.D., Honored with the Academy for Radiology and Biomedical Imaging Research's Distinguished Investigator Award

Nautilus Biotechnology to Participate in the Inaugural Guggenheim Healthcare Conference

Nautilus Biotechnology Reports Third Quarter 2024 Financial Results

$NAUT Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Guggenheim initiated coverage on Nautilus Biotechnology with a new price target

Jefferies resumed coverage on Nautilus Biotechnology with a new price target

Morgan Stanley initiated coverage on Nautilus Biotechnology with a new price target

Recent Analyst Ratings for
$NAUT

$NAUT
Insider Trading

$NAUT
Financials

$NAUT
SEC Filings

$NAUT
Leadership Updates

$NAUT
Market Insights

$NAUT
Insider Purchases

$NAUT
Large Ownership Changes

$NAUT
Press Releases

$NAUT
Analyst Ratings